CommercialCoverageMedium impact
In Vitro Chemoresistance and Chemosensitivity Assays
Blue Cross & Blue Shield of Mississippi·MS · Oncology·Medical Policy
We identified it
Jun 20, 2026
Summary
BCBS Mississippi has updated their policy on in vitro chemoresistance and chemosensitivity assays, confirming that all such tests (including Extreme Drug Resistance Assays, Histoculture Drug Response Assays, fluorescent cytoprint assays, and ChemoFx assays) are considered investigational and not covered. This policy clarifies that these cancer testing methods do not meet medical necessity standards.
Action Required
Immediately: Billing team must verify that any claims for in vitro chemoresistance or chemosensitivity assays are flagged as non-covered investigational services for BCBS Mississippi members. Update system notes to indicate these tests require patient financial responsibility discussions before ordering. Inform oncology providers that these assays will not be reimbursed by BCBS Mississippi.